



Dr Giorgio Roscigno, FIND Chief Executive Officer

Dr Giorgio Roscigno has 20 years experience in the pharmaceutical industry, in medical and clinical research of antinfectives. He joined the industry after five years field medical experience in Ethiopia, Sudan and the Democratic Republic of Congo. He has been at different times, the Medical Director for Africa, Asia, the European Clinical Research Director for Antinfectives, and finally the International Medical Director for Antinfectives with Aventis in Paris (France).

During his years with industry, Dr. Roscigno has been closely associated with the clinical work and the subsequent registration (including FDA) of all the tuberculosis (TB) fixed dose combinations containing rifampin.

He also contributed to the clinical development of rifapentine, a long acting rifamycin, approved by FDA in 1998.

Dr Roscigno has also led the clinical research work on DFMO eflornithine, for the treatment of sleeping sickness, and the coordination of the African multicenter clinical trial, in collaboration with TDR. The outcome of this trial represented the clinical package for FDA approval in 1992.

In 2000, Dr Roscigno was among the founding members of the Global Alliance for TB Drug Development, a non for profit public-private partnership dedicated to the discovery of new TB drugs. He left the industry and joined the GATB, initially as Acting Chief Executive Officer, then Strategic Development Director.

In May 2003, Dr Roscigno joined FIND as Chief Executive Officer.